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Aim: Mast cells are versatile innate immune cells and are reported to promote vascular 
inflammation and neointimal lesion formation, thereby contributing to the development of 
vascular stenosis and atherosclerosis. However, it is not clear whether mast cells also regulate 
vascular matrix remodelling in established neointima. This study addressed the hypothesis that 
perivascular mast cells regulate neointimal matrix remodelling using a mouse vein graft model. 
Methods: The impact of mast cells on neointimal remodelling was investigated using mast 
cell-deficient animals in both normolipidaemic (KitW-sh/W-sh) and hyperlipidaemic (apoE-/-KitW-sh/W-sh) 
conditions. The effect of perivascular mast cells on vascular matrix remodelling, including 
collagen and elastin deposition, was investigated using a local mast cell reconstitution method 
that selectively repopulated mast cells around the carotid artery (where the vein graft was 
inserted) in KitW-sh/W-sh mice. Results: In normolipidaemic vein grafts (KitW-sh/W-sh vs. the wild 
type control C57BL/6J), collagen synthesis was not affected by mast cell deficiency at 4 weeks. 
In contrast, neointimal elastin was reduced by 6.5-fold in mast cell-deficient KitW-sh/W-sh mice, 
which was prevented by perivascular mast cell reconstitution. Mast cell deficiency induced a 
similar reduction in neointimal elastin in hyperlipidaemic mice (apoE-/-KitW-sh/W-sh vs. apoE-/-), 
with a significant increase in cell proliferation and neointimal area at 4 weeks. Conclusion: 
Mast cells appear to promote elastin deposition in vein grafts and this may lead to further 
suppression of cell proliferation and neointimal thickening under hyperlipidaemic conditions.
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INTRODUCTION
Mast cells are versatile innate immune cells, well-
known for their role in inflammation and innate 
immunity.[1,2] Despite the wide distribution of mast 
cells in arterial adventitia and perivascular connective 
tissue, our understanding of the influence of mast 
cells in vascular disease is limited. In recent years, 
accumulating evidence suggests that mast cells 
promote vascular inflammation and contribute to the 
progression of a number of vascular diseases including 
atherosclerosis, aortic aneurysm and vein graft 
neointima hyperplasia.[3-6] Systemic activation of mast 
cells using dinitrophenyl-albumin increased plaque size in 
apoE-/- mice, whilst selective stimulation of perivascular 
mast cells had no impact on plaque formation but 
destabilised established plaque with increased intra-
plaque haemorrhage.[7] Compound 48/80, another 
mast cell activator, demonstrated a similar effect to 
promote atherosclerosis development, which was 
inhibited by the mast cell stabiliser cromolyn.[8,9] In 
addition to pharmacological manipulation of mast cell 
function, studies using genetic mast cell deficiency 
(as a consequence of spontaneous mutation in the 
promoter region of the c-kit gene[10]) also confirmed 
the detrimental effect of mast cells in atherosclerosis.[3] 
Mechanistic studies revealed that activated mast 
cells synthesised and released a wide range of pro-
inflammatory factors including interleukin (IL)-6 and 
IL-8, interferon gamma, tumournecrosis factor alpha, 
histamine, chymase and tryptase. Consequently, mast 
cells exacerbated vascular inflammation with increased 
intra-plaque leukocyte infiltration, lipid uptake, vascular 
matrix degradation and subsequent plaque expansion 
and destabilisation.[6]
In vein graft disease, neointimal hyperplasia is 
the major cause of restenosis.[11,12] The neointima 
formation in vein grafts is mainly driven by acute 
vascular inflammation. In a mouse vein graft model, the 
acute inflammation usually lasts less than two weeks 
following grafting surgery.[13,14] The neointima thereafter 
undergoes a remodelling stage where neointimal 
cells differentiate into smooth muscle-like cells and 
synthesise large amount of vascular matrix including 
collagen and elastin as a process of arterialisation.[12,15] 
The remodelling process stabilises neointimal cells and 
prevents chronic neointimal thickening. We and others 
have found that perivascular mast cells boost acute 
vein graft inflammation via an increase in cytokine 
secretion and activation of the complement system.[14,16] 
This leads to a significant rise in cell proliferation in 
the acute inflammation stage (one week after vein 
graft implantation) and more neointima formation. 
However, it is not clear whether perivascular mast 
cells also regulate vascular matrix remodelling after 
resolution of acute inflammation. This is particularly 
important under pro-atherosclerotic conditions as 
vascular smooth muscle cells from pro-atherosclerotic 
animals are more susceptible to chronic proliferation in 
response to mitogenic stimuli.[17] In the present study, 
we performed interpositional vein grafting in mast cell 
deficient mouse lines bred on both a normolipidaemic 
and hyperlipidaemic genetic background (KitW-sh/W-sh 
and apoE-/-KitW-sh/W-sh) to address this question.
METHODS
Animals
All experiments which involved animals conformed 
to Directive 2010/63/EU of the European Parliament 
and also to the UK Home Office Animal (Scientific 
Procedures) Act 1986 and were performed under 
Project Licence PPL 60/4114. In addition, ethical 
permission for the study had been granted by the 
University of Strathclyde ethical review committee.
Mice carrying the KitW-sh/W-sh mutation were used in 
this study as a mast cell deficiency model. KitW-sh/W-sh 
is a spontaneous mutation in the promoter region of 
the c-kit gene which is critical for mast cell survival.[10] 
As the c-kit gene itself is intact, c-kit expression is 
preserved to some extent in the early life of these mice. 
Consequently, systemic mast cell deficiency does 
not develop until 4 weeks old. Jackson Laboratories 
(USA) was the original supplier of both the KitW-sh/W-sh 
and apoE-/- mice and these were subsequently bred in-
house. Both strains were on a C57BL/6J background. 
In order to generate a hyperlipidaemic mouse line 
lacking mast cells, apoE-/- and KitW-sh/W-sh mice were 
cross-bred. For the normolipidaemic KitW-sh/W-sh mice, 
the congenic control was C57BL/6J while for the 
hyperlipidaemic apoE-/-KitW-sh/W-sh mice, the apoE-/- was 
the congenic control. All mice were maintained on a 
cycle of 12-h periods of light and dark and allowed 
access to normal chow diet and water ad libitum. Male 
mice (about 10 to 20 weeks old) were used in this 
study.
Surgery
The mouse vein graft model is a well-established 
model for studying neointimal hyperplasia.[13,14] Briefly, 
i.p. injection of sodium pentobarbital (60 mg/kg) was 
used as an anaesthetic agent with top-up doses 
administered as appropriate and depending on the 
depth of anaesthesia demonstrated by the pedal 
withdrawal reflex. All animals received perioperative 
analgesic cover (buprenorphine; 0.05 mg/kg body 
weight, s.c.). From a donor mouse, the thoracic inferior 
vena cava was carefully harvested. In all experiments 
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the donor mouse was a male mouse of the same 
genotype. In the recipient mouse, the right common 
carotid artery was prepared by isolating it, tying two 
sutures around the middle and cutting. A nylon cuff 
was then sleeved onto the distal arterial end. In order 
to graft the vein onto artery rather than nylon cuff, the 
artery was everted back over the cuff and ligated using 
8/0 silk suture (Ethicon, Livingston, UK). The proximal 
end of the carotid artery was prepared in an identical 
fashion. The vena cava to be grafted was then sleeved 
onto each arterial end in turn and tied into position with 
8/0 suture. Twenty-eight days after grafting, mice were 
euthanised by a rising concentration of CO2. The neck 
was opened and the vein graft removed and placed in 
physiological bathing solution.
Perivascular mast cell reconstitution
In a previous study from our laboratory, we established 
a reliable method for reconstituting mast cells locally 
to the perivascular region. The advantage of this 
method is that it re-establishes a local mast cell 
reconstitution in the KitW-sh/W-sh mice without mast cells 
being present elsewhere.[14] Thus, this method allows 
the role of perivascular mast cells to be investigated 
without the consequences of systemic mast cell 
reconstitution, which can include ectopic mast cell 
accumulation and abnormal distribution of mast cells 
in target organs/tissues.[10,14] Briefly, C57BL/6J mice 
were used as the source of bone marrow cells and 
these were cultured with mast cell-differentiating 
media (containing murine IL-3 and stem cell factor; 
PeproTech, New Jersey, USA) for 4 weeks as we 
have described previously.[14] To confirm that the 
cultured cells were in fact differentiated into mast 
cells, flow cytometry with anti-c-Kit and anti-FcεRI 
antibodies (eBioscience, Hatfield, UK) was used.[14] To 
investigate the impact of local reconstitution of mast 
cells on neointima formation within the vein graft, the 
perivascular area of the right common carotid artery 
was injected with the bone marrow-derived mast cells 
(BMMCs) as follows. Briefly, the recipient KitW-sh/W-sh 
mouse was anaesthetised with sodium pentobarbital 
as previously described and the common right carotid 
artery was exposed. BMMCs were injected around the 
artery (1 million cells per mouse). A suture of size 6/0 
was used to close the wound and the animal was kept 
for 4 weeks to allow repopulation of the perivascular 
area with a mast cell population similar to that seen 
in wild type (C57BL/6) mice.[14] Vein graft surgery was 
performed 4 weeks after mast cell reconstitution.
Histology and immunostaining
Vein grafts were perfusion-fixed to maintain graft 
patency and then stored overnight in 10% formalin 
before being embedded in paraffin. For each vein 
graft, serial sections of 5 µm thickness were cut from 
5 evenly divided regions from the proximal to the 
distal end. In all cases, 5 slides (1 slide from each 
region) were stained as outlined below and the values 
averaged for each vein graft. The advantage of this 
method is that the average value gives an indication 
of the value from the whole of the graft rather than one 
discrete area which may not be representative of the 
graft as a whole. For general and gross morphology 
and for planimetry studies, haematoxylin and eosin 
staining was used and the slides were photographed 
and analysed using Image pro plus software (Media 
Cybernetics, Marlow, UK). Collagen was stained by 
picrosirius red and visualised under polarised light. 
As with other stains used, at least 5 slides were used 
from the length of the graft to give a mean intensity 
of the total fluorescent signal and this value was used 
for comparison of collagen content between groups. 
Elastin was identified by Verhoeff Van Gieson staining 
and mean intensity of light absorption of the bluish 
dark stain within the neointima was quantified. To avoid 
batch-to-batch variation, for each staining protocol, all 
the vein graft samples were stained at one time. For 
immunostaining, slides were de-waxed and pressure-
cooked in citrate buffer to retrieve antigens of interest. 
To study proliferation in vein grafts, one slide per vein 
graft was stained using an antibody to the marker Ki67 
(rabbit anti-Ki67 antibody, Abcam). The percentage cell 
proliferation was presented as the ratio of Ki67 positive 
nuclei over total nuclei in the wall of the vein graft.
Statistics
In all experiments, data are presented as mean 
± standard error of the mean where n refers to the 
number of mice. To make comparisons between two 
groups an unpaired Student’s t-test was used as long 
as the data had a normal distribution and, for data 
not normally distributed, the non-parametric Mann 
Whitney test was used. To compare data from multiple 
groups a one-way analysis of variance (ANOVA) 
with Tukey’s post hoc test was used as appropriate. 
Statistical analyses were performed using Graph 
Pad Prism v6.04. In all comparisons, a significant 
difference was assumed when P < 0.05.
RESULTS
Mast cells promote elastin but not collagen 
deposition in vein grafts by 4 weeks
Significant collagen deposition was identified in all 
vein grafts at 4 weeks. The majority of collagen was 
present in the neo-adventitia and perivascular area 
[Figure 1A]. In contrast, elastin was only detected in 
the neointima [Figure 1B and C]. Mast cell deficiency 
(KitW-sh/W-sh) had no impact on collagen deposition, 
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but suppressed elastin deposition by 6.5 fold. Local 
mast cell reconstitution (4 weeks before vein graft 
implantation) rescued the impaired elastin deposition 
in KitW-sh/W-sh vein grafts (23.5 ± 4.8 vs. 3.6 ± 1.1 vs. 
26.4 ± 4.4 arbitrary units/mm2; C57BL/6J vs. 
KitW-sh/W-sh vs. KitW-sh/W-sh + lcMC; P < 0.01 by one-way 
ANOVA). Mast cell deficiency in hyperlipidaemic mice 
induced a similar suppression of neointimal elastin 
(37.6 ± 4.0 vs. 13.4 ± 2.9 arbitrary units/mm2; apoE-/- 
vs. apoE-/-KitW-sh/W-sh; P < 0.01 by Student’s t-test).
Mast cell deficiency increased chronic 
neointimal proliferation and thickening in 
apoE-/- mice but not in C57BL/6J mice
Mast cell deficiency moderately suppressed 
neointima formation in normolipidaemic mice 4 
weeks after grafting (1.7 × 105 ± 0.2 × 105 vs. 1.1 
× 105 ± 0.1 × 105 µm2; C57BL/6J vs. KitW-sh/W-sh; P 
< 0.01 by Student’s t-test), but induced a 2-fold 
increase in the hyperlipidaemic mice (1.9 × 105 
± 0.2 × 105 vs. 4.2 × 105 ± 0.8 × 105 µm2; apoE-/- 
vs. apoE-/-KitW-sh/W-sh; P < 0.01 by Student’s t-test; 
Figure 2A and B). Cell proliferation within the vein 
graft at 4 weeks was very low in both C57BL/6J 
and KitW-sh/W-sh (2.1 ± 0.5% vs. 1.8 ± 0.3%; C57BL/6J 
vs. KitW-sh/W-sh), but significantly elevated in apoE-/-
KitW-sh/W-sh compared to apoE-/- (1.9 ± 0.5% vs. 5.3 ± 
1.4%; apoE-/- vs. apoE-/-KitW-sh/W-sh; P < 0.05 by Mann 
Whitney test; Figure 2A and C).
Figure 1: Mast cell deficiency suppressed elastin deposition in vein graft. (A) Picrosirus red staining demonstrated that both C57BL/6J and 
KitW-sh/W-sh vein grafts synthesised large amount of collagen (in green, yellow and red colour) in the adventitia and perivascular connective 
tissue by 4 weeks. No statistical difference was detected in collagen content between groups; (B and C) Elastin deposition was restricted 
to the vein graft neointima (visualised by Verhoeff Van Gieson staining, indicated by arrows). Mast cell deficient KitW-sh/W-sh vein grafts 
contained a significantly lower level of elastin versus congenic C57BL/6J vein grafts, which was rescued by local mast cell reconstitution. 
Mast cell deficiency in hyperlipidaemic mice (apoE-/-) also significantly suppressed elastin deposition in the vein graft by 4 weeks. n = 6; **P 
< 0.01. One-way analysis of variance plus Tukey post hoc test was used for multiple group comparison and unpaired student’s t-test for two 
group comparison
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DISCUSSION
This study demonstrates firstly that perivascular mast 
cells elevate neointimal elastin deposition under both 
normolipidaemic and hyperlipidaemic conditions, and 
secondly that they suppress neointimal thickening in 
hyperlipidaemic mice possibly via down regulation of 
cell proliferation within the vein graft.
Elastin is one of the fundamental structural proteins 
of the arterial wall that regulates vascular elasticity 
and stabilises smooth muscle cells.[18] The present 
study demonstrates that mast cells play a previously 
unrecognised role in promotion of elastin deposition 
during vein graft remodelling. The causality is 
demonstrated by the data showing that mast cell 
deficiency reduced, and mast cell reconstitution 
rescued, elastin deposition in the vein graft. 
Although the exact mechanism of how mast cells 
regulate elastin deposition is not yet clear, there is 
a consensus within the literature that heparin is the 
potential mediator. The evidence for the involvement 
of heparin is three-fold. Firstly, mast cells are the only 
cell type that produces heparin in vivo.[19] Secondly, 
heparin is known to promote elastogenesis and 
supress neointima hyperplasia in injured arteries 
and vascular grafts.[20,21] Being the most negatively 
charged molecule in biological systems, heparin 
covalently binds to the positively charged tropoelastin 
to accelerate tropoelastin coacervation and elastic 
fibre formation.[22-24] However, the very short half-
life of heparin limits its pharmacological potency for 
therapeutic purposes.[25] Only continuous intravenous 
delivery,[26-28] but not short term treatment,[29] inhibited 
neointima thickening. Interestingly, perivascular 
delivery of heparin required a much smaller dose 
and was more effective in suppression of neointima 
hyperplasia,[20,25] which matches the source of 
endogenous heparin from perivascular mast cells. 
Thirdly, mast cell granules are enriched with heparin 
and the heparin-based particles are capable of 
long distance travel within tissue[30] which makes 
perivascular mast cells an ideal and indeed the only 
source for continuous heparin supply to assist vascular 
elastogenesis.
It is intriguing that mast cell-dependent elastin 
deposition had a divergent impact on neointimal 
hyperplasia in normolipidaemic and hyperlipidaemic 
vein grafts. This could be a consequence of the 
different dynamics of neointima formation and vascular 
matrix remodelling. In normolipidaemic mice, the 
neointima formation is driven by acute inflammation 
and proliferation which peak within one week and 
are complete by 2 weeks.[13,31] During the 3rd and 
4th weeks, the neointimal proliferation decreases 
Figure 2: Mast cell deficiency in hyperlipidaemic mice increased neointima area with elevated chronic cell proliferation. (A) Representative 
images of cell proliferation in 4-week-old vein grafts. Proliferating cells were labelled using an antibody against Ki67 (green) and cell nuclei 
by DAPI (blue). The neointimal area in apoE-/- KitW-sh/W-sh vein grafts was significantly higher than all other groups (B), associated with 
elevated cell proliferation by 4 weeks (C). n > 6 for all groups; **P < 0.01 by one-way analysis of variance plus Tukey post hoc test
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over 10-fold and the majority of the neointimal cells 
transdifferentiate into smooth muscle-like cells that 
initiate vascular matrix remodelling including elastin 
deposition.[13,14,18,31] Therefore, elastin is unlikely to 
regulate the early events of neointima formation in the 
normolipidaemic vein graft. The modest reduction in 
neointimal area in the KitW-sh/W-sh vein graft is attributed 
to the damped cell proliferation during the first week 
rather than altered elastin deposition.[14]
Both our data and the literature[32] demonstrated 
that apoE-/- mice, when fed on normal chow diet, do 
not demonstrate any enhancement of neointimal 
hyperplasia. The low cell proliferation level in apoE-/- 
vein grafts at 4 weeks in the current study suggests 
that the neointima was stabilised, similar to that in 
C57BL/6J. These observations are in contrast with 
in vitro evidence that apoE-/- smooth muscle cells 
are predisposed to a higher rate of proliferation.[17] 
One clear difference between data from cell cultures 
and neointima formation in vivo is the absence of 
the rich extracellular matrix environment. ApoE-/- vein 
grafts at 4 weeks contained large amounts of elastin 
that can stabilise neointimal smooth muscle cells.[18] 
The reduction in neointimal elastin in apoE-/-KitW-sh/W-sh 
grafts was correlated with a dramatic increase in cell 
proliferation within the vein graft wall, suggesting that 
the presence of elastin is an important protective 
mechanism against chronic smooth muscle cell 
proliferation under pro-atherogenic conditions.
Mast cells, as innate immune cells, are well-
documented to have pro-inflammatory effects in many 
pre-clinical vascular studies.[6] Induction of mast cell 
activation in a pro-inflammatory environment, either 
using pharmacological activators or long term western 
diet in pro-atherosclerotic mouse models (apoE-/- or 
LDLr-/-), was a common feature of these studies. The 
widely accepted paradigm is that high levels of pro-
inflammatory factors and proteinases released by 
activated mast cells promote vascular inflammation 
and development of vascular lesions. Indeed activated 
mast cells may be the explanation for the clinical 
correlation between mast cell-mediated allergic 
disease and atherosclerosis.[33] However, the role of 
unstimulated mast cells in normal vasculature or in 
stable vascular disease is not fully understood. The 
current study provides the first evidence that mast cells 
could exert a positive effect in vascular remodelling 
via regulation of elastin deposition. Our unpublished 
data suggests that the expression of inflammatory 
cytokines in vein grafts during the remodelling stage 
(4 weeks after implantation) is negligible. We therefore 
speculate that the mast cell-dependent regulation of 
elastin is independent of immunological/inflammatory 
mechanisms, but mediated by heparin (as discussed 
above) or some unknown mechanisms.
The mast cell-elastin-axis could potentially be 
extrapolated to vascular development as the first 
appearance of mast cells around the foetal aorta 
is before the formation of aortic elastic laminae.[34] 
This suggests that mast cells may also contribute 
to the foetal arteriogenesis by assisting formation 
of elastic fibres. In addition to the perivascular area, 
the mast cell population is clearly enriched in all the 
elastic tissue/organs including arteries, skin and lung, 
indicating a universal link between mast cells and 
elastin. Under pathological conditions, an increase 
of mast cell number is often associated with elastin-
related tissue fibrosis.[35,36] In a skin photodamage 
model, chronic ultraviolet light exposure increases 
skin mast cell number accompanied by a 3.6 fold 
elevation in elastin content, which was not observed 
in the mast cell-deficient KitW/W-v mice.[37] Similar 
correlation was also present in human skin.[38] Non-
elastic organs, such as the liver usually hosts only a 
very small population of mast cells.[39] In liver disease, 
an increase of hepatic elastin is one of the most 
distinct features of hepatic fibrosis and cirrhosis,[36] 
correlated with a significant increase in hepatic mast 
cells.[39] In contrast to other leukocyte recruitment, the 
increase of mast cell number persisted with the chronic 
progress of hepatic cirrhosis,[40] suggesting the mast 
cell-mediated pathological elastin accumulation was 
beyond inflammatory mechanisms.
Collectively, accumulating evidence suggests that the 
mast cell-elastin axis may be a universal mechanism 
that regulates physiological and pathological elastin 
metabolism. Our findings, in line with other literature, 
raise the question of whether mast cells regulate 
vascular elastin metabolism via mechanisms 
independent from their immunological function. More 
comprehensive investigation is required to clarify the 
complex role of mast cells in vascular development 
and remodelling.
The current study used a mast cell-deficient mouse 
model (KitW-sh/W-sh) and local mast cell reconstitution 
to demonstrate that perivascular mast cells promoted 
neointimal elastin remodelling in vein grafts. Limited 
by the experimental period, it was not clear whether 
perivascular mast cells merely accelerated the elastin 
deposition in the 4-week time window, or permanently 
increased the elastin level in the neointima. Unlike 
the elastic lamina in healthy arteries, the elastic fibres 
in the neointima were diffuse. The presence of mast 
cells only increased the amount of elastic fibres but 
did not improve the structure of the matrix. Further 
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experiments are required to clarify whether the 
quantitative increase in elastin content has a positive 
impact on vascular compliance and vasomotor 
function, which may also influence the neointima 
hyperplasia.
In conclusion, this is the first study to demonstrate the 
mast cell-dependent regulation of elastin deposition 
in vein grafts, and subsequent suppression of chronic 
vein graft hyperplasia in hyperlipidaemic mice. This 
study sheds new light on the function of perivascular 
mast cells on vascular lesion formation and 
remodelling, and provides new targets for therapeutic 
intervention for vein graft failure and other stenotic 
vascular disease.
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